Skip to main content
Premium Trial:

Request an Annual Quote

Techne Acquires Reagents Maker Tocris

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Techne today announced that it has acquired life science research reagents maker Tocris Holdings and its subsidiaries for £75 million ($124 million) in cash.

Bristol, UK-based Tocris makes reagents that are used in a wide variety of research areas, such as angiogenesis, cell metabolism, signal transduction, stem cells, as well as in pharmacological studies of ion channels, nuclear receptors, transporter molecules, and enzymes. Its offerings will be combined with those of Techne's R&D Systems subsidiary, which provides purified cytokines, antibodies, and assay kits that are sold to biomedical researchers and clinical research labs.

Tocris had 2010 revenues of £11.7 million and EBITDA of £7.4 million. Techne expects the acquisition to add around $3.5 million to its fourth-quarter 2011 sales and said that it is expected to be slightly dilutive to its fourth-quarter 2011 and fiscal-year 2012 net earnings.

Tocris will continue its product development, marketing, and sales activities from Bristol and will coordinate with R&D Systems and its re3lated European and Chinese entities to expand product distribution worldwide.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.